Marc Hurlbert
Showing 1–2 of 2 transcripts.
- Milken Institute1h 1m
The Next Wave of Immunotherapy and Cancer Treatments | Milken Institute Global Conference 2024
Marc Hurlbert, Gina Carithers, Friedrich Graf Finckenstein, Anusha Kalbasi, Connie Pfeiffer, Sunil Verma, Frederick Finckenstein, Neil Verma, Anusha Singhal
Major research organizations like the Melanoma Research Alliance and the Prostate Cancer Foundation have funded over $1 billion in studies that pioneered immune checkpoint inhibitors and novel T-cell therapies for melanoma and prostate cancer. Recent advancements include the approval of Iovance's tumor-infiltrating lymphocyte treatment for solid tumors and the development of bispecific agents that reduce manufacturing delays, though challenges regarding high costs, autoimmune side effects, and the need for broader genetic screening persist. Clinical strategies are shifting toward neoadjuvant trials and combination therapies with antibody-drug conjugates to improve patient outcomes before standard care options are exhausted.
- Milken Institute1h 1m
AI and Machine Learning in Cancer Medicine
Marc Hurlbert, Maurice Ferré, Colin Hill, Mike Nohaile, Susan Swetter, Amanda Hall, Mark Shieldsmann, Lisa Desjardins
The Melanoma Research Alliance, which has directed over $250 million toward global melanoma initiatives, convened experts to address rising mortality rates and the critical need for advanced early detection technologies. Panelists from Stanford, GNS Healthcare, and Amgen demonstrated how deep learning algorithms now match human dermatologists in image classification while causal modeling predicts treatment responses to accelerate precision medicine. Despite current limitations regarding data quality, algorithmic bias, and regulatory hurdles, these advancements aim to bridge rural care gaps and eventually substitute traditional clinical trials with robust in-silico simulations.